# Filing Detail

Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001104659-24-041120
Filing Date
2024-03-29
Accepted
2024-03-29 15:33:30
Documents
5

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 424B5 | tm2213007-9_424b5.htm | 424B5 | 1062143
2 | GRAPHIC | lg_adagene-4clr.jpg | GRAPHIC | 12592
3 | GRAPHIC | tm2213007d1-pc_neobody4c.jpg | GRAPHIC | 320003
4 | GRAPHIC | tm2213007d1-tbl_program4c.jpg | GRAPHIC | 105986
5 | GRAPHIC | tm2213007d1-fc_corpobw.jpg | GRAPHIC | 89307
| Complete submission text file | 0001104659-24-041120.txt |  | 1789935

Mailing Address 4F, BUILDING C14, NO. 218, XINGHU STREET SUZHOU INDUSTRIAL PARK JIANGSU F4 00000
Business Address 4F, BUILDING C14, NO. 218, XINGHU STREET SUZHOU INDUSTRIAL PARK JIANGSU F4 00000 86-512-87773632
Adagene Inc. (Filer) CIK: 0001818838 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-264486 | Film No.: 24803955
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)